Login Register Cart 0
Generic placeholder image

Current Hypertension Reviews

Editor-in-Chief

ISSN (Print): 1573-4021
ISSN (Online): 1875-6506

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The High Potency of Polymeric Nanoparticles in the Drug Delivery System for Hypertension Treatment: A Systematic Review

Author(s): Fatemeh Mohammadipour, Aliasghar Kiani and Arash Amin*

Volume 18, Issue 1, 2022

Page: [54 - 63] Pages: 10

DOI: 10.2174/1573402117666210921121622

Price: $65

Abstract

Background: Polymeric nanomaterials with sizes ranging from 10 to 1000 nm are one of the most widely used types of nanoparticles with ideal properties in the drug delivery systems. Here, we decided to systematically review the antihypertensive effects of polymeric nanomaterials in vitro, in vivo, and clinical trials.

Methods: The present review was conducted based on the 06- PRISMA guideline; whereas five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without time limitation were used for searching the publications related to antihypertensive effects of natural and synthetic polymeric nanoparticles.

Results: The results demonstrated that among 1701 papers, 25 papers including 11 in vitro (44%), 6 in vivo (24%), 7 in vitro / in vivo (28%), and 1 in vitro / ex vivo (4%) up to 2020, met the inclusion criteria for discussion in this systematic review. The most used nanoparticles were poly-(lactic- co-glycolic) acid nanoparticle (PLGANPs) (7, 29.2%), chitosan based nanoparticles (6, 25%), followed by polylactide acid nanoparticles (5, 20.8%).

Conclusion: We concluded that the high potency of polymeric nanoparticles in the drug delivery system was for hypertension treatment. Although the accurate mechanisms are not fully understood; however, some mechanisms, such as sustained release forms with increased bioavailability, increasing oral bioavailability and improving the oral and non-oral absorption, counteracting excessive superoxide and decreasing blood pressure, etc. can be related to these nanoparticles.

Keywords: Hypertension, blood pressure, polymeric nanoparticles, chitosan, polylactic acid, poly-(lactic-co-glycolic) acid.

« Previous Next »
Graphical Abstract

[1]
Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25(6): 1172-81.
[http://dx.doi.org/10.1093/ije/25.6.1172] [PMID: 9027521]
[2]
WHO New data highlight increases in hypertension, diabetes incidence. WHO 2013.
[3]
Kannel WB. Hypertension as a risk factor for cardiac events-epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21(Suppl. 2): S27-37.
[http://dx.doi.org/10.1097/00005344-199321002-00006] [PMID: 7692148]
[4]
Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood- pressure-related disease, 2001. Lancet 2008; 371(9623): 1513-8.
[http://dx.doi.org/10.1016/S0140-6736(08)60655-8] [PMID: 18456100]
[5]
Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the american heart association. Hypertension 2013; 61(6): 1360-83.
[http://dx.doi.org/10.1161/HYP.0b013e318293645f] [PMID: 23608661]
[6]
Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A. A review of the role of statins in heart failure treatment. Curr Clin Pharmacol 2020; 15(1): 30-7
[http://dx.doi.org/10.1016/j.amjmed.2007.11.025] [PMID: 18374693]
[7]
Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289(16): 2083-93.
[PMID: 12709466]
[8]
Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal medications in cardiovascular medicine. J Am Coll Cardiol 2017; 69(9): 1188-99.
[http://dx.doi.org/10.1016/j.jacc.2016.11.078] [PMID: 28254182]
[9]
Cicha I, Unterweger H, Lyer S, Janko C, Friedrich RP, Ottler MP¨. Nanomedicine for cardiovascular disorders. Nanomedicine 2019; 23: 3007-12.
[http://dx.doi.org/10.2217/nnm-2019-0391]
[10]
Albalawi AE, Alanazi AD, Baharvand P, Sepahvand M, Mahmoudvand H. High potency of organic and inorganic nanoparticles to treat cystic echinococcosis: an evidence-based review. Nanomaterials. 2020; 10(12): 2538.
[11]
Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomedicine 2014; 9: 1-15.
[PMID: 24363556]
[12]
Nafari A, Cheraghipour K, Sepahvand M, Shahrokhi G, Gabal E, Mahmoudvand H. Nanoparticles: New agents toward treatment of leishmaniasis. Parasite Epidemiol Control 2020; 10: e00156.
[http://dx.doi.org/10.17219/acem/31802] [PMID: 26768624]
[13]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[14]
Sun H, Liu D, Li Y, Tang X, Cong Y. Preparation and in vitro/in vivo characterization of enteric-coated nanoparticles loaded with the antihypertensive peptide VLPVPR. Int J Nanomedicine 2014; 9: 1709-16.
[http://dx.doi.org/10.2147/IJN.S56092] [PMID: 24729706]
[15]
Nag P, Rajput R, Dhaliwal S, Kumar S, Prajapat D, Singh M. Formulation and characterization of propranolol nanoparticles for transmucosal nasal drug delivery. In: Macromolecular SymposiaWiley-VCH Verlag. 2015; pp. 32-8.
[16]
Auwal SM, Zarei M, Tan CP, Basri M, Saari N. Improved In Vivo Efficacy of Anti-Hypertensive Biopeptides Encapsulated in Chitosan Nanoparticles Fabricated by Ionotropic Gelation on Spontaneously Hypertensive Rats. Nanomaterials (Basel) 2017; 7(12): 421. Available from: http://www.mdpi.com/2079-4991/7/12/421
[http://dx.doi.org/10.3390/nano7120421] [PMID: 29207480]
[17]
Singh A, Deep A. Formulation and evaluation of nanoparticles containing losartan potassium. Int J Pharm Res Technol 2011; 1.
[18]
Sharma M, Sharma R, Jain DK. Preparation, characterization and evaluation of nebivolol loaded chitosan nanoparticles. J Drug Deliv Ther 2018; 8(2): 118-22.
[http://dx.doi.org/10.22270/jddt.v8i2.1730]
[19]
Niaz T, Shabbir S, Manzoor S, et al. Antihypertensive nano-ceuticales based on chitosan biopolymer: Physico-chemical evaluation and release kinetics. Carbohydr Polym 2016; 142: 268-74. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014486171630011X
[http://dx.doi.org/10.1016/j.carbpol.2016.01.047] [PMID: 26917399]
[20]
Chadha R, Bhandari S, Kataria D, Gupta S, Singh Jain D. Exploring the potential of lecithin/chitosan nanoparticles in enhancement of antihypertensive efficacy of hydrochlorothiazide. J Microencapsul 2012; 29(8): 805-12. Available from: http://www.tandfonline.com/doi/full/10.3109/02652048.2012.692399
[http://dx.doi.org/10.3109/02652048.2012.692399] [PMID: 22681125]
[21]
Chadha R, Bhandari S, Kataria D, Gupta S. Exploring lecithin/chitosan nanoparticles of ramipril for improved antihypertensive efficacy. J Nanopharm Drug Deliv 2013; 1(2): 173-81.
[http://dx.doi.org/10.1166/jnd.2013.1014]
[22]
Savalia K, Manickam DS, Rosenbaugh EG, et al. Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration. Free Radic Biol Med 2014; 73: 299-307.
[http://dx.doi.org/10.1016/j.freeradbiomed.2014.06.001] [PMID: 24924945]
[23]
Jana U, Kumar A, Manna K, Mohanta P. Preparation and in vitro characterization of felodipine loaded eudragit® Rs100 nanoparticles. Int J Pharm Pharmaceut Sci 2014; 6(4): 564-7.
[24]
Kecel-Gündüz S, Budama-Kilinc Y, Cakir Koc R, et al. Computational design of Phe-Tyr dipeptide and preparation, characterization, cytotoxicity studies of Phe-Tyr dipeptide loaded PLGA nanoparticles for the treatment of hypertension. J Biomol Struct Dyn 2018; 36(11): 2893-907.
[http://dx.doi.org/10.1080/07391102.2017.1371644] [PMID: 28835169]
[25]
Si S, Li H, Han X. Sustained release olmesartan medoxomil loaded PLGA nanoparticles with improved oral bioavailability to treat hypertension. J Drug Deliv Sci Technol 2020; 55: 101422.
[http://dx.doi.org/10.1016/j.jddst.2019.101422]
[26]
Öztürk AA, Martin Banderas L, Cayero Otero MD, Yenilmez E, Yazan Y. New approach to hypertension treatment: Carvediol-loaded PLGA nanoparticles, preparation, in vitro characterization and gastrointestinal stability. Lat Am J Pharm 2018; 37(9): 1730-41.
[27]
Ingalls GG. Targeted PLGA Nanoparticles for the Sustained Release of Hypertensive Drugs. 2019. Available from: http://nrs.harvard.edu/urn-3:HUL.InstRepos:42004071
[28]
Castro PM, Baptista P, Madureira AR, Sarmento B, Pintado ME. Combination of PLGA nanoparticles with mucoadhesive guar-gum films for buccal delivery of antihypertensive peptide. Int J Pharm 2018; 547(1-2): 593-601. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378517318303612
[http://dx.doi.org/10.1016/j.ijpharm.2018.05.051] [PMID: 29800740]
[29]
Yu T, Zhao S, Li Z, et al. Enhanced and extended anti-hypertensive effect of VP5 nanoparticles. Int J Mol Sci 2016; 17(12): 1977. Available from: http://www.mdpi.com/1422-0067/17/12/1977
[http://dx.doi.org/10.3390/ijms17121977] [PMID: 27898022]
[30]
Leroueil-Le Verger M, Fluckiger L, Kim YI, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm 1998; 46(2): 137-43. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0939641198000150
[http://dx.doi.org/10.1016/S0939-6411(98)00015-0] [PMID: 9795032]
[31]
Dorniani D, Umar Kura A, Zobir Bin Hussein M, Fakurazi S, Halim Shaari A, Ahmad Z. Controlled-release formulation of perindopril erbumine loaded PEG-coated magnetite nanoparticles for biomedical applications. J Mater Sci 2014; 49: 8487-97.
[http://dx.doi.org/10.1007/s10853-014-8559-7]
[32]
Kim YI, Fluckiger L, Hoffman M, Lartaud-Idjouadiene I, Atkinson J, Maincent P. The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol 1997; 120(3): 399-404. Available from: http://doi.wiley.com/10.1038/sj.bjp.0700910
[http://dx.doi.org/10.1038/sj.bjp.0700910] [PMID: 9031742]
[33]
Niaz T, Nasir H, Shabbir S, Rehman A, Imran M. Polyionic hybrid nano-engineered systems comprising alginate and chitosan for antihypertensive therapeutics. Int J Biol Macromol 2016; 91: 180-7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0141813016304664
[http://dx.doi.org/10.1016/j.ijbiomac.2016.05.055] [PMID: 27212217]
[34]
Basu T, Pal B, Singh S. Fabrication of core–shell PLGA/PLA–pNIPAM nanocomposites for improved entrapment and release kinetics of antihypertensive drugs. Particuology 2018; 40: 169-76. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1674200117301979
[http://dx.doi.org/10.1016/j.partic.2017.10.002]
[35]
Chinh NT, Trang NTT, Mai TT, et al. Polylactic Acid/Chitosan Nanoparticles Loading Nifedipine: Characterization Findings and In Vivo Investigation in Animal. J Nanosci Nanotechnol 2018; 18(4): 2294-303. Available from: http://www.ingentaconnect.com/content/10.1166/jnn.2018.14537
[http://dx.doi.org/10.1166/jnn.2018.14537] [PMID: 29442895]
[36]
Jana UT, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Preparation and in vitro characterization of Felodipine loaded Eudragit® RS100 nanoparticles. Int J Pharm Pharm Sci 2014; 6: 564-7.
[37]
Jana U, Mohanty AK, Pal SL, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study. Nano Convergence 2014; 1: 31.
[38]
Pechanova O, Barta A, Koneracka M, et al. Protective effects of nanoparticle-loaded aliskiren on cardiovascular system in spontaneously hypertensive rats. Molecules 2019; 24(15): E2710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31349653
[http://dx.doi.org/10.3390/molecules24152710] [PMID: 31349653]
[39]
Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A. A review of the role of statins in heart failure treatment. Curr Clin Pharmacol 2020; 15(1): 30-7.
[http://dx.doi.org/10.2174/1574884714666190802125627] [PMID: 31376825]
[40]
Yadav P, Singh MN, Saraf SA, Katiyar N, Singh AK, Yadav I. Formulation and evaluation of novel sericin nanoparticles for buccal delivery of antihypertensive drug. Int J Appl Pharm Sci Res 2017; 3(01): 1-11.
[http://dx.doi.org/10.21477/ijapsr.v3i01.10421]
[41]
Al Meslmani BM, Mahmoud GF, Bakowsky U. Development of expanded polytetrafluoroethylene cardiovascular graft platform based on immobilization of poly lactic-co-glycolic acid nanoparticles using a wet chemical modification technique. Int J Pharm 2017; 529(1-2): 238-44.
[http://dx.doi.org/10.1016/j.ijpharm.2017.06.091] [PMID: 28689963]
[42]
Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014; 129(8): 896-906.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002870] [PMID: 24305567]
[43]
Korin N, Kanapathipillai M, Matthews BD, et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012; 337(6095): 738-42.
[http://dx.doi.org/10.1126/science.1217815] [PMID: 22767894]
[44]
Lee PC, Zan BS, Chen LT, Chung TW. Multifunctional PLGA-based nanoparticles as a controlled release drug delivery system for antioxidant and anticoagulant therapy. Int J Nanomedicine 2019; 14: 1533-49.
[http://dx.doi.org/10.2147/IJN.S174962] [PMID: 30880963]
[45]
Kravanja G, Primožič M, Knez Ž, Leitgeb M. Chitosan-based (Nano) materials for novel biomedical applications. Molecules 2019; 24(10): 1960.
[http://dx.doi.org/10.3390/molecules24101960] [PMID: 31117310]
[46]
Al Mohammed HI, Khudair Khalaf A, E Albalawi A, et al. Chitosan-Based Nanomaterials as Valuable Sources of Anti-Leishmanial Agents: A Systematic Review. Nanomaterials. 2021; 11(3): 689.
[47]
Shah U, Joshi G, Sawant K. Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design. Mater Sci Eng C 2014; 35(1): 153-63. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0928493113006097
[http://dx.doi.org/10.1016/j.msec.2013.10.038] [PMID: 24411363]

Rights & Permissions Print Cite
Article Metrics
46
1
© 2024 Bentham Science Publishers | Privacy Policy